OP
GNMK

Omni Partners’s GenMark Diagnostics, Inc GNMK Stock Holding History

Omni Partners’s Portfolio GNMK Stock Details GNMK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		$36.8M Buy
+1,540,671
New +$28.6M 1.81% 17

Other funds holding GNMK

Wasatch Advisors
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Magnetar Financial
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
VI
Versor Investments New York $47.5M AUM 100.43% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Omni Partners's GNMK Position: Q1 2021 in Review

Omni Partners opened a new position in GenMark Diagnostics, Inc (GNMK) in Q1 2021: 1,540,671 shares worth $36.8M. The stake represents 1.81% of the portfolio and ranks #17 among its holdings.

164 funds tracked by Wall St. Rank hold GNMK as of Q1 2021.

  • Omni Partners held 1,540,671 shares of GenMark Diagnostics, Inc worth $36.8M as of Q1 2021.
  • GenMark Diagnostics, Inc was a new Omni Partners position in Q1 2021.
  • GenMark Diagnostics, Inc made up 1.81% of Omni Partners's portfolio in Q1 2021, its #17 holding.
  • 164 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q1 2021.

Based on Omni Partners's 13F filing for Q1 2021, filed 17 May 2021.